2879 results about "Chemo therapy" patented technology

The disclosure relates to methods, compositions, and combinations for the treatment of endometrial cancer. Specifically, the disclosure relates to methods of treating endometrial cancer in a subject in need thereof, comprising administering to the subject one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor. The disclosure also relates to combinations for use in the treatment of endometrial cancer comprising one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

The invention relates to the technical field of medical data processing and prediction, and discloses a chemotherapy adverse reaction prediction and intervention system based on big data. The system integrates an unstructured disease course text and structured inspection data of a patient, generates a time-series symptom event, and performs time window alignment and fusion on the time-series symptom event, a medication record and a physical sign monitoring stream to form a multi-dimensional time-series data block. The system is combined with an external medical knowledge base to construct a dynamic association network among symptoms, medicines and physiological indexes, and dynamically calculates the confidence coefficient of an adverse reaction mode according to real-time data. By using a predictive model of the timing attention mechanism, the system can output a continuous curve of patient risk over time. The system automatically matches and generates a personalized intervention instruction sequence containing specific measures and execution time windows according to key time points and modes when the risk curve exceeds a threshold value. According to the invention, dynamic and advanced early warning and accurate intervention of adverse reaction risks of chemotherapy are realized.

The invention discloses a group of gene markers for predicting or evaluating neoadjuvant chemotherapy response of breast cancer and application of the gene markers. The gene markers comprise CCNA2, CCND1, CD52, ESR1 and FAM234B. The system for predicting or evaluating the neoadjuvant chemotherapy reaction of the breast cancer is constructed on the basis of the gene marker, and can accurately predict or evaluate whether the breast cancer patient has the risk that complete remission cannot be achieved after neoadjuvant chemotherapy, and discriminate whether the breast cancer patient can benefit from the neoadjuvant chemotherapy reaction; therefore, whether the breast cancer patient can be subjected to neoadjuvant chemotherapy or not is accurately predicted, medical intervention is performed in time, and the method has important clinical reference value.

The invention discloses a coordination system and method for intelligent appointment treatment of daytime chemotherapy, and relates to the technical field of medical information, and the system comprises an information processing unit which is used for obtaining the medical information of a target patient, constructing a comprehensive diagnosis and treatment information model comprising the diagnosis and treatment parameters of the patient, and generating an initial diagnosis and treatment node sequence based on the comprehensive diagnosis and treatment information model; the optimization unit is used for receiving the initial diagnosis and treatment node sequence from the information processing unit, adjusting the priority of each node in the initial diagnosis and treatment node sequence according to a first influence factor, and generating a diagnosis and treatment path after reordering; and the management unit is used for generating a daily chemotherapy appointment strategy and a follow-up visit plan of the target patient based on the diagnosis and treatment path sent by the optimization unit, and sending reminding content containing appointment key information through a patient terminal. Through multi-dimensional priority comprehensive evaluation and a dynamic adjustment mechanism, resource utilization and diagnosis and treatment paths of daytime chemotherapy are optimized, intelligent appointment and real-time response are realized, and treatment efficiency and patient experience are improved.

The invention provides a child abdominal common solid tumor activity image evaluation method and device and a medium, and the method comprises the steps: capturing the change information of a focus on a vein phase image after plain scanning and enhancement through a 3D convolutional neural network model, carrying out the intelligent silhouette, and generating an enhancement region and the enhancement degree of the focus after chemotherapy, thereby achieving the evaluation of the activity of a child abdominal common solid tumor. And finally, integrating all the information to perform intelligent diagnosis, judging the tumor activity, and forming an artificial intelligence auxiliary activity evaluation scheme after chemotherapy of the abdominal solid tumor. According to the method, the automatic enhancement degree quantitative evaluation of the hepatoblastoma, the nephroblastoma and the neuroblastoma of the children is realized through automatic tumor segmentation and registration subtraction image calculation by utilizing the plain scanning and enhanced CT image, so that the focus characteristics are extracted from multiple angles, the image information is fully mined, and the accuracy of the diagnosis is improved. Accuracy and sensitivity of activity discrimination after chemotherapy of the solid abdominal tumor of children can be obviously improved.

The invention discloses a longitudinal analysis-based lung cancer chemotherapy combined immunotherapy patient symptom prediction method, which comprises the following steps: S1, collecting a multi-modal medical data set of a patient, and carrying out data preprocessing; S2, carrying out time sequence integration on the preprocessed multi-modal medical data set to construct a longitudinal analysis data set; s3, constructing a symptom weight adaptive modeling method based on an attention mechanism; s4, forming a symptom-treatment causal relationship evaluation model; s5, inputting real-time multi-modal medical data of the patient into the symptom-treatment causal relationship evaluation model, and classifying prediction results; s6, generating an individual symptom risk assessment report of the patient according to a prediction result; s7, the clinician dynamically optimizes the chemotherapy dose, the immunotherapy dose and the drug use time of the patient based on the individualized symptom risk assessment report. The invention provides an effective technical means for accurately optimizing a lung cancer chemotherapy and immunotherapy combined scheme.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

The invention relates to the field of medical information management, in particular to a children malignant tumor treatment process and follow-up visit electronic management system and a children malignant tumor treatment process and follow-up visit electronic management method. The method comprises the steps that the body surface area of a patient is calculated, and the chemotherapy drug dosage in each cycle is calculated based on the body surface area of the patient; performing cycle-by-cycle accumulation on the chemotherapeutic drug dose in each cycle to obtain an actual accumulated dose; calculating and standardizing the specific numerical value of each curative effect index based on the actual accumulated dose, and calculating a comprehensive therapeutic effect score by combining the importance weight of each curative effect index; and calculating the disease-free survival rate based on the actual accumulated dose and the comprehensive treatment effect score. The problems that at present, most medicine dosage calculation methods neglect the special physiological features of children, a treatment monitoring system lacks dynamic adjustment support in the treatment process, a follow-up management system is insufficient in quantitative analysis capacity for long-term prognosis, and personalized long-term health management suggestions cannot be provided for patients are solved.

The invention provides a composition for promoting hair regeneration after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: modifying the surface of a gold nanocage with polydopamine, loading the modified gold nanocage on an exosome, complexing magnesium ions and zinc ions to prepare a modified exosome, preparing a nano drug-loaded liposome from curcumin, resveratrol and epigallocatechin gallate, mixing the nano drug-loaded liposome with the modified exosome to prepare a multi-layer liposome, and preparing the multi-layer liposome from the nano drug-loaded liposome. And mixing with a penetration enhancer, and adding into a temperature-sensitive hydrogel system to prepare the composition for promoting hair regeneration after chemotherapy. The composition for promoting hair regeneration after chemotherapy has a good transdermal absorption promoting effect, can slowly release drugs, promotes hair follicles to be converted from a resting stage to a growing stage under the synergistic effect of the drugs, regulates and controls multiple pathways (such as anti-apoptosis, angiogenesis promotion and anti-inflammation) at the same time, is matched with a complex pathological mechanism of hair regeneration after chemotherapy, and can promote hair regeneration after chemotherapy. Wide application prospects are realized.

The invention belongs to the technical field of medicines, particularly relates to application of deaminotyrosine in preparation of a medicine for treating cardiomyopathy caused by anthracycline medicines, discovers that DAT can relieve cardiotoxicity caused by DOX to a great extent, and can provide a new thought for recovery of patients after chemotherapy and expansion of clinical application of DOX.

The invention discloses an esophageal cancer neoadjuvant chemotherapy and post-immunization pathology complete remission prediction system and method, and relates to the field of medical image processing, and the system comprises an image processing module which is used for carrying out the standardized processing of an input image, and segmenting a tumor region in the image; the feature extraction module is used for extracting voxel-level radiomics features from the tumor area; the feature screening module is used for screening out a plurality of voxel-level radiomics features with the most predictive capability; and the pathology prediction module is used for generating a comprehensive feature vector according to the segmented input image and the screened voxel-level radiomics features, and predicting the curative effect of the combination of neoadjuvant chemotherapy and immunotherapy according to the comprehensive feature vector. According to the technical scheme provided by the invention, the accuracy of predicting complete pathologic remission after neoadjuvant chemotherapy and immunotherapy of esophageal cancer can be improved, the defect that the heterogeneity in tumors cannot be considered in a traditional imaging omics technology is overcome, and the method has a relatively high application value.

The invention provides a tumor treatment effect prediction method based on multi-modal data, and relates to the field of medical artificial intelligence. The method comprises the following steps: collecting magnetic resonance image data, histopathological section images and clinical baseline data of a tumor patient and a treatment response evaluation record after neoadjuvant chemotherapy; the collected image information is preprocessed; feature extraction is carried out based on the preprocessed image information; screening a feature subset with the highest prediction value from the extracted features; constructing a radiopathomics fusion model by using the feature subset with the highest prediction value; evaluating the radiopathomics fusion model; and predicting the tumor treatment effect by using the evaluated radiopathomics fusion model. The problems that an existing tumor neoadjuvant chemotherapy (NACT) curative effect prediction method is low in accuracy, poor in generalization ability, lack of multi-modal data fusion and insufficient in model interpretability are solved.

The invention relates to the field of tumor treatment, in particular to application of a small molecule compound in preparation of a medicine for treating colorectal cancer. The AKT pathway specific inhibitor MK2206 disclosed by the invention can inhibit the proliferation of colorectal cancer, induce cell cycle arrest, induce apoptosis and enhance the sensitivity of colorectal cancer cells to oxaliplatin and 5-fluorouracil. The MK2206 is used for inhibiting the activity of an AKT pathway, so that the effects of inhibiting proliferation of colorectal cancer cells, inducing apoptosis of the colorectal cancer cells and improving the sensitivity of the colorectal cancer cells to chemotherapeutic drugs oxaliplatin and 5-fluorouracil are achieved, and the MK2206 can be used for preparing drugs for treating the colorectal cancer.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The invention relates to the field of multi-modal learning, in particular to a colorectal cancer drug chemotherapy reaction prediction system and a storage medium, and a computer program in the storage medium executes the following steps: constructing a PDO model and a PDOX model based on tumor cells; obtaining a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate of the colorectal cancer patient by utilizing the PDO model and the PDOX model; based on the obtained medical record and pathological examination of the colorectal cancer patient, obtaining the age, ASA score, Ki-67 index, combined positive score and clinical outcome of the patient, and further constructing a sample set in combination with a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate; and constructing a model for predicting the chemotherapy reaction of the colorectal cancer drug on the basis of multi-factor logistic regression, training and evaluating the model by using the sample set, and performing chemotherapy guidance on a to-be-treated colorectal cancer patient. The problems that in the prior art, chemotherapy reaction prediction of the colorectal cancer patient is not accurate enough and low in efficiency are solved.

The invention provides application of a PDLIM4 gene in preparation of a medicine for inhibiting non-small cell lung cancer proliferation, belongs to the technical field of cancer suppressor gene research, and finds that the PDLIM4 gene is highly expressed in non-small cell lung cancer tumors, and the prognosis of a patient with the highly expressed PDLIM4 gene is good; the proliferation of the non-small cell lung cancer cells overexpressed with the PDLIM4 gene is inhibited, and the proliferation of the non-small cell lung cancer cells knocked down with the PDLIM4 gene is accelerated, so that the reagent capable of realizing the overexpression of the PDLIM4 gene is confirmed to be of great significance for inhibiting the proliferation of the non-small cell lung cancer cells. The overexpression of the PDLIM4 gene in the non-small cell lung cancer cells can enhance the chemotherapy effect of the chemotherapy drug adriamycin, and can be used as a chemotherapy sensitizer. The BRD4 is an upstream regulatory factor for increasing the expression of the PDLIM4 gene in the non-small cell lung cancer, and can be used for promoting the expression of the PDLIM4 gene.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The invention provides an anti-cold stimulation nursing device used after tumor chemotherapy, and belongs to the field of nursing tools. Comprising a wrapping piece; a heat conduction pipe is arranged in the wrapping part, the two ends of the heat conduction pipe are movably connected with a heating device, the heating device comprises an outer shell, an air blowing structure and a heat adjusting structure are arranged in the outer shell, and a leakage-proof structure is connected between the heat conduction pipe and the outer shell; the air blowing structure comprises a center shaft rod rotationally connected to the axis of the outer shell, a variable frequency motor is fixedly connected to the interior of the outer shell, and the output end of the variable frequency motor is fixedly connected with a first bevel gear. The air conditioner can be used by people of different heights, heat can be rapidly generated, cyclic heating is formed, heat in all areas is more uniform, the heat can be automatically adjusted according to the air speed, and the sealing effect of the structure at the joint of the outer shell and the heat passing pipe is automatically adjusted according to the air speed.

The invention relates to a breast cancer cardiotoxicity risk prediction system based on multi-modal data fusion. According to the system, multi-source heterogeneous medical data such as electronic health records, dynamic electrocardiogram monitoring, echocardiography video streams, chemotherapy medication time sequence data and pathological section images are collected in real time through a distributed architecture, and the storage efficiency is optimized by adopting a layered compression strategy. According to the system, risk indexes are mapped to a three-dimensional heart thermodynamic diagram, key feature contribution degrees are displayed in an associated manner, and a dynamic risk knowledge map is established to reveal a toxicity generation path. The system deploys an incremental learning mechanism to realize continuous optimization of the model, guarantees data security through differential privacy and federal learning, sets a real-time early warning feedback loop, triggers clinical intervention when the risk exceeds a threshold value, and dynamically adjusts the weight of the model according to the feedback of a physician, thereby remarkably improving the prediction accuracy and clinical applicability.

The present invention relates to a bispecific antibody comprising a first variable domain that can bind to an extracellular portion of human epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of human MET prooncogene receptor tyrosine kinase (cMET) for use in a method of treatment of cancer in an individual, the subject has received a previous treatment with i) a third generation EGFR tyrosine kinase inhibitor, or ii) chemotherapy and tyrosine kinase inhibitor, or iii) a cMET tyrosine kinase inhibitor.

The invention discloses a method for constructing a tumor organoid by using stromal stem cells, which improves the survival rate and success rate of the tumor organoid by improving the introduction of the stromal stem cells in the construction of the human tumor organoid, especially for tumor samples which fail to be cultured by the currently disclosed method. The organoid constructed by the invention can be used for analyzing biological characteristics of human tumor organoid; and a clinical tumor drug sensitivity prediction platform is established by taking a tumor organ as a model tool, so that the effectiveness of a treatment scheme is evaluated more systematically and comprehensively, and support is provided for screening an optimal individualized precise treatment scheme for a tumor patient. In addition, on the platform, screening, verification and mining can be carried out on tumor batch chemotherapy drugs or other potential anti-cancer small molecule drugs in clinical application.

The invention discloses a targeted nano delivery system based on curcumin (Cur) and near-infrared aggregation-induced emission (AIE) molecule BDTA and application of the targeted nano delivery system in treatment of glioblastoma (GBM), and belongs to the field of biomedicine. The nano platform is composed of nanoparticles (MPMs (at) Cur-BDTA NPs) modified by a macrophage membrane, curcumin and BDTA are combined by adopting a coprecipitation method, and the targeting property of the nano platform to tumors is enhanced through modification of the macrophage membrane. The nanometer platform combines the functions of photo-thermal therapy (PTT), photodynamic therapy (PDT) and chemotherapy, and can achieve multiple treatment effects. The curcumin improves PTT sensitivity by down-regulating expression of heat shock protein HSP-70 in the platform, and effectively improves photothermal conversion efficiency (87.6%) and singlet oxygen generation amount (1.7 times higher than that of a control group) through a Foster resonance energy transfer (FRET) mechanism. In a glioblastoma in-vitro experiment, the nano platform shows a synergistic treatment effect of photo-thermal, photodynamic and chemotherapy. The invention provides an intelligent treatment platform integrating photo-thermal treatment, photodynamic treatment and chemotherapy, and provides an efficient and safe innovative treatment strategy for precise treatment of glioblastoma.

The invention discloses a PARP1 selective protein degradation agent and an application of the PARP1 selective protein degradation agent in tumor resistance. The degradation agent has the following structural formula. Wherein the 3-ethyl-7-((4-(pyridine-3-yl) piperazine-1-yl) methyl) quinoxaline-2 (1H)-ketone part is a PARP1 target protein ligand, and L is a connecting unit; and B is an E3 ubiquitin ligase ligand. The PARP1 selective protein degradation agent prepared by the preparation method disclosed by the invention can be used for effectively degrading PARP1 protein, inhibiting cell proliferation and inducing tumor cell apoptosis. Meanwhile, when the compound is combined with chemotherapeutic drugs, the effect of enhancing the chemotherapeutic effect is achieved, almost no physiological toxicity exists, and the compound is expected to provide an ideal way for improving treatment of various diseases caused by PARP1 excessive activation. # imgabs0 #

The invention discloses a breast cancer neoadjuvant chemotherapy curative effect prediction method and system, and relates to the medical image processing and analysis technology, and the method comprises the steps: carrying out the Macenko dyeing normalization of a sample HE pathological image of a patient; extracting a tissue region from the normalized sample HE pathological image by using an HEST method; inputting the extracted tissue region into a Prov-GigaPath network, extracting a feature vector of a specified dimension under set parameters, and performing dimension reduction on the extracted feature vector; inputting the feature vectors subjected to dimension reduction into an ABMIL model, and training the feature vectors; and predicting the HE pathological image of the patient based on the trained ABMIL model, and visualizing the prediction result by using the attention score of the trained ABMIL model. According to the method provided by the invention, multi-level complex features such as cellular morphology and tissue structure in the HE image can be automatically mined, and the accuracy and reliability of prediction are greatly improved.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.